Intratumoral Immunotherapies Currently Undergoing Development & Updated on Efficacy Data
Time: 11:00 am
day: Day Two
Details:
- Review of all intratumoral immunotherapies that have been approved or have shared efficacy and safety results from clinical development
- Challenges for intratumoral immunotherapy development, best endpoint to target
- Predictive biomarkers; how and when assess them
